1. High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy
   Ji-Youn Sung et al, 2022, Biomedicines CrossRef
2. Pre-treatment Neutrophil-to-Lymphocyte Ratio significantly affects progression free survival in positive EGFR mutation advanced lung adenocarcinoma with EGFR-TKI treatment in Bali, Indonesia
   Ni Putu Ayu Widiasari et al, 2023, Romanian Journal of Internal Medicine CrossRef
3. Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion
   Hiroshi Nokihara et al, 2022, BMC Cancer CrossRef
4. Prognostic impact of pleural effusion in patients with malignancy: A systematic review and meta‐analysis
   Yuan Yang et al, 2022, Clinical and Translational Science CrossRef
5. The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer
   Long Wang et al, 2021, Cancer Management and Research CrossRef
6. Top advances of the year: Targeted therapy for lung cancer
   Maisam Makarem et al, 2024, Cancer CrossRef
7. Prognostic value of venous thromboembolism in patients with advanced pancreatic cancer: a systematic review and meta-analysis
   Kaifeng Su et al, 2024, Frontiers in Oncology CrossRef
8. Risk factors for rib metastases of lung cancer patients with high-uptake rib foci on 99Tcm-MDP SPECT/CT
   Yuanyuan YANG et al, 2024, The Quarterly Journal of Nuclear Medicine and Molecular Imaging CrossRef
9. Advancing Treatment of Bone Metastases through Novel Translational Approaches Targeting the Bone Microenvironment
   Nan Sethakorn et al, 2022, Cancers CrossRef
10. Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidence
    Luyao Ao et al, 2022, Journal of Experimental & Clinical Cancer Research CrossRef